{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:20Z","timestamp":1790910080328,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019450","name":"Verastem Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006696","name":"Fondazione Guido Berlucchi","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/501100006696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ygyno.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T19:05:30Z","timestamp":1714763130000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Preclinical in vitro and in vivo activity of the RAF\/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas"],"prefix":"10.1016","volume":"187","author":[{"given":"Cem","family":"Demirkiran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Manavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zipponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang-Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.04.010_bb0005","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0010","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30537","article-title":"Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas","volume":"140","author":"Jones","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"Mcconechy","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and Ifosfamide in patients with Carcinosarcoma of the uterus or ovary: an NRG oncology trial","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.26.8326","article-title":"Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"28","author":"Powell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of raf activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective mek inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF\u2013MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-Centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144250","article-title":"Drug discovery targeting focal adhesion kinase (Fak) as a promising cancer therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766) \u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"41","author":"Banerjee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2022.05.005","article-title":"Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor","volume":"166","author":"Tymon-Rosario","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.04.010_bb0105","article-title":"Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:42:18Z","timestamp":1762231338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"alternative-id":["S0090825824001951"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical in vitro and in vivo activity of the RAF\/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}